SCHEMBL9252905

SCHEMBL9252905

CC(C)N1Cc2ccncc2C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.40
KCNH2 Q12809 3/20 0.39
GRM5 P41594 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CYP11B2 P19099 1/20 0.38
CDC25B P30305 1/20 0.37
GRM1 Q13255 1/20 0.36
THRB P10828 1/20 0.36
CYP3A4 P08684 1/20 0.36
STING1 Q86WV6 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAP3K5 Q99683 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9259806 0.87 IDH1 (0.43) IDH1KCNH2GRM5MAOAMAOB
SCHEMBL21212262 0.77 CYP11B2 (0.41) GRM5MAOAMAOBCYP11B2CDC25B
SCHEMBL9252931 0.75 TIPARP (0.37) ALDH1A1MITFLMNARAB9ASMN1; SMN2
SCHEMBL9252937 0.75 TIPARP (0.37) ALDH1A1MITFLMNARAB9ASMN1; SMN2
SCHEMBL120182 0.75 ALOX15 (0.57) THRBALDH1A1LMNARAB9ASMN1; SMN2
SCHEMBL9259830 0.74 SIGMAR1 (0.42) CYP11B2ALDH1A1MITFLMNARAB9A
SCHEMBL9261369 0.74 SIGMAR1 (0.42) CYP11B2ALDH1A1MITFLMNARAB9A
SCHEMBL22021654 0.74 CYP11B2 (0.41) MAOAMAOBCYP11B2CDC25BSTING1
SCHEMBL122927 0.73 PIK3CG (0.40) MAOAMAOBCYP11B2CDC25BCYP3A4
SCHEMBL17517151 0.71 MAP3K5 (0.42) KCNH2GRM5MAOAMAOBGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 US disclosed
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND SHIONOGI & CO., LTD. (JP) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 IDH1 2500/4885KCNH2 4751/4885GRM5 2626/4885
US-20120135997-A1 PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND BACE1, STS, APP IDH1 500/4885KCNH2 3151/4885GRM5 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.